294 related articles for article (PubMed ID: 33641249)
1. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.
Ko K; Kananazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Kuriyama S; Matsuda A; Yoshida H
Cancer Med; 2021 Mar; 10(6):2003-2012. PubMed ID: 33641249
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases.
Iwai T; Yamada T; Takahashi G; Takeda K; Koizumi M; Shinji S; Matsuda A; Yokoyama Y; Hara K; Ueda K; Ohta R; Taniai N; Yoshida H
Eur J Surg Oncol; 2020 Jan; 46(1):108-114. PubMed ID: 31431321
[TBL] [Abstract][Full Text] [Related]
3. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
4. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
6. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
[TBL] [Abstract][Full Text] [Related]
7. Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer.
Yoruker EE; Ozgur E; Keskin M; Ozgur I; Gezer U
Turk J Gastroenterol; 2021 Sep; 32(9):720-726. PubMed ID: 34609300
[TBL] [Abstract][Full Text] [Related]
8. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
9. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
10. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer.
Lapin M; Oltedal S; Tjensvoll K; Buhl T; Smaaland R; Garresori H; Javle M; Glenjen NI; Abelseth BK; Gilje B; Nordgård O
J Transl Med; 2018 Nov; 16(1):300. PubMed ID: 30400802
[TBL] [Abstract][Full Text] [Related]
11. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
12. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer.
Li CL; Ho MC; Lin YY; Tzeng ST; Chen YJ; Pai HY; Wang YC; Chen CL; Lee YH; Chen DS; Yeh SH; Chen PJ
Hepatology; 2020 Dec; 72(6):2063-2076. PubMed ID: 32171027
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence.
Yamamoto M; Kurokawa Y; Miyazaki Y; Makino T; Takahashi T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
World J Surg; 2016 Aug; 40(8):1904-9. PubMed ID: 26969673
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; Cullinane C; Ita M; Corrigan M; O'Leary DP; Redmond HP
Surg Oncol; 2022 Jun; 42():101753. PubMed ID: 35594723
[TBL] [Abstract][Full Text] [Related]
15. Computational challenges in detection of cancer using cell-free DNA methylation.
Sharma M; Verma RK; Kumar S; Kumar V
Comput Struct Biotechnol J; 2022; 20():26-39. PubMed ID: 34976309
[TBL] [Abstract][Full Text] [Related]
16. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
18. Monitoring gastric cancer progression with circulating tumour DNA.
Hamakawa T; Kukita Y; Kurokawa Y; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Taniguchi K; Takiguchi S; Mori M; Doki Y; Kato K
Br J Cancer; 2015 Jan; 112(2):352-6. PubMed ID: 25490524
[TBL] [Abstract][Full Text] [Related]
19. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
